Evidence map›Paper›PMID 40337849›Full record

ArticleLab on a chip2025

Sample-sparing multiplexed antibody Fc biomarker discovery using a reconfigurable integrated microfluidic platform.

Hanhao Zhang, Divya Bhakta, Anushka Saha, Sai Preetham Peddireddy, Shumin Bao, Lei Li, Sukwan Handali, W Evan Secor, Lucia A O Fraga, Jessica K Fairley and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Lab on a chip, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hanhao ZhangDepartment of Biomedical Engineering, Georgia Institute of Technology, 315 Ferst Dr NW, Atlanta, GA 30332, USA. aniruddh.sarkar@bme.gatech.edu.
Divya BhaktaDepartment of Biomedical Engineering, Georgia Institute of Technology, 315 Ferst Dr NW, Atlanta, GA 30332, USA. aniruddh.sarkar@bme.gatech.edu.
Anushka SahaDepartment of Biomedical Engineering, Georgia Institute of Technology, 315 Ferst Dr NW, Atlanta, GA 30332, USA. aniruddh.sarkar@bme.gatech.edu.
Sai Preetham PeddireddyDepartment of Biomedical Engineering, Georgia Institute of Technology, 315 Ferst Dr NW, Atlanta, GA 30332, USA. aniruddh.sarkar@bme.gatech.edu.
Shumin BaoDepartment of Chemistry and Center for Diagnostics & Therapeutics, Georgia State University, Atlanta, GA, 30303, USA.
Lei LiDepartment of Chemistry and Center for Diagnostics & Therapeutics, Georgia State University, Atlanta, GA, 30303, USA.ORCID 0000-0002-1146-0761
Sukwan HandaliDivision of Parasitic Diseases and Malaria, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.
W Evan SecorDivision of Parasitic Diseases and Malaria, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.
Lucia A O FragaFederal University of Juiz de Fora, Juiz de Fora, Minas Gerais 36036-900, Brazil.
Jessica K FairleyDepartment of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA 30307, USA.
Aniruddh SarkarDepartment of Biomedical Engineering, Georgia Institute of Technology, 315 Ferst Dr NW, Atlanta, GA 30332, USA. aniruddh.sarkar@bme.gatech.edu.ORCID 0000-0002-9327-1525

Funding

Implementing a Maternal health and PRegnancy Outcomes Vision for Everyone (IMPROVE)UL1TR002378 · NCATS · EMORY UNIVERSITY · PI Andres J Garcia, Elizabeth O. Ofili · 2017 to 2026
$92.1M
Microscale Multiplexed Antibody Fc Profiling and Nanoscale Electronic Detection for Rapid and Scalable Point-of-Care Diagnosis of TuberculosisR01AI182322 · NIAID · GEORGIA INSTITUTE OF TECHNOLOGY · PI Aniruddh Sarkar · 2024 to 2026
$1.1M
NCATS NIH HHS UL1 TR002378NIAID NIH HHS R01 AI182322
6 · The paper itself

Abstract

Control of endemic infectious diseases is often impeded by the lack of sensitive and specific yet easy-to-obtain biomarkers. Antibody fragment crystallizable (Fc) regions, such as Fc glycosylation, which are modulated in a pathogen-specific and disease-state-specific manner have emerged as potential such biomarkers. However current methods to perform large-scale antigen-specific antibody Fc feature screening for biomarker discovery often require too much sample volume, cost and expertise to be realistically realizable in many disease contexts. Here we present a simple, flexible and reconfigurable microfluidic device, made using rapid prototyping techniques, that can perform highly multiplexed and high-throughput biomarker discovery targeting both antibody fragment antigen-binding (Fab) and Fc features including antigen specificity, antibody isotypes, subclasses,

Indexed as

Immunoglobulin Fc FragmentsLab-On-A-Chip DevicesMicrofluidic Analytical TechniquesBiomarkersEquipment DesignHumansBiomarkersImmunoglobulin Fc Fragments

Identifiers

PMID40337849
PMCPMC12060099

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.